CD109 and neoplasm: To explore the clinical relevance of CD109 in human oral SCC, we assessed the expression of CD109, TGF-β and phosphoSmad2 (P-Smad2) in 52 human oral SCC (OSCC) tumor samples using tissue microarray immunohistochemistry.